| Drug Name |
Pancrelipase |
| Drug ID |
BADD_D01664 |
| Description |
Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands.[L2509] The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510] For further information on the components of this mixture please visit [DB11065], [DB11066] and [DB13147]. |
| Indications and Usage |
The use of pancrelipase amylase is part of the pancreatic enzyme replacement therapy. This therapy is indicated for the treatment of pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis or any other medically defined pancreatic disease that might require it.[A32721, A32736] Pancreatic diseases are associated with the deterioration of pancreatic parenchyma and of the dual physiological functions of the pancreas. Once established, pancreatic insufficiency results in malnutrition, weight loss, and steatorrhea.[A32723] |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB00085
|
| KEGG ID |
D05349
|
| MeSH ID |
D020799
|
| PubChem ID |
8519
|
| TTD Drug ID |
D0A5DJ
|
| NDC Product Code |
31387-137; 51421-001; 57298-807; 57298-803; 0032-1212; 59767-004; 59767-008; 0032-1203; 73562-208; 68621-0061; 31387-165; 54809-1024; 73562-104; 31387-205; 57298-804; 59767-024; 0032-1224; 31387-219; 54809-1025; 57298-806; 59767-016; 0032-1206; 0032-3016; 54809-1026; 54809-3823; 54809-9048; 57298-802; 57298-805 |
| UNII |
FQ3DRG0N5K
|
| Synonyms |
Pancrelipase | Cotazyme | Creon | Encron | Ilozyme | Ku-Zyme | Ku Zyme | Lipram | Pancrease | Pancrecarb | Pancron | Panokase | Pertzye | Protilase | Ultrase | Viokase | Zymase | Cotazym-S | Cotazym S |
